Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Sep;68(3):641–644. doi: 10.1038/bjc.1993.400

A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

E G de Vries 1, J A Gietema 1, P Workman 1, J E Scott 1, A Crawshaw 1, H J Dobbs 1, I Dennis 1, N H Mulder 1, D T Sleijfer 1, P H Willemse 1
PMCID: PMC1968400  PMID: 8353055

Abstract

Piritrexim is a lipid-soluble antifolate which, like methotrexate, has a potent capacity to inhibit dihydrofolate reductase. We performed a multicentre phase II study with piritrexim in patients with locally advanced or metastatic breast cancer. Twenty-four patients of which sixteen had received prior chemotherapy, were initially treated with 25 mg piritrexim orally administered trice daily for four days, repeated weekly, with provision for dose escalation or reduction according to observed toxicity. Of twenty-one patients evaluable for tumour response, one patient achieved a partial response which lasted for 24 weeks. Three patients had stable disease during 12 weeks of treatment, seventeen had progressive disease. Pirtrexim was generally well tolerated, in eighteen patients the dose could be escalated. Myelotoxicity was the most frequent observed toxicity of this piritrexim regimen. Leucopenia and thrombocytopenia grade 3/4 occurred in 38% of the patients sometime during treatment. Pharmacokinetic analysis of piritrexim in three patients during the first treatment cycle, revealed peak levels 1 to 2 h after an oral dose, with a trend towards a higher peak plasma levels and AUCs on the fourth dosing day compared with the first dosing day. In conclusion, orally administered piritrexim appears to be a regimen with little activity in patients with locally advanced or metastatic breast carcinoma.

Full text

PDF
641

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamson P. C., Balis F. M., Miser J., Arndt C., Wells R. J., Gillespie A., Aronson L., Penta J. S., Clendeninn N. J., Poplack D. G. Pediatric phase I trial, pharmacokinetic study, and limited sampling strategy for piritrexim administered on a low-dose, intermittent schedule. Cancer Res. 1992 Feb 1;52(3):521–524. [PubMed] [Google Scholar]
  2. Adamson P. C., Balis F. M., Miser J., Wells R. J., Bleyer W. A., Williams T. E., Gillespie A., Penta J. S., Clendeninn N. J., Poplack D. G. Pediatric phase I trial and pharmacokinetic study of piritrexim administered orally on a five-day schedule. Cancer Res. 1990 Aug 1;50(15):4464–4467. [PubMed] [Google Scholar]
  3. Carter S. K. Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev. 1976 Sep;3(3):141–174. doi: 10.1016/s0305-7372(76)80020-5. [DOI] [PubMed] [Google Scholar]
  4. Duch D. S., Edelstein M. P., Bowers S. W., Nichol C. A. Biochemical and chemotherapeutic studies on 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido[2,3-d]pyrimidine (BW 301U), a novel lipid-soluble inhibitor of dihydrofolate reductase. Cancer Res. 1982 Oct;42(10):3987–3994. [PubMed] [Google Scholar]
  5. Feun L. G., Gonzalez R., Savaraj N., Hanlon J., Collier M., Robinson W. A., Clendeninn N. J. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol. 1991 Mar;9(3):464–467. doi: 10.1200/JCO.1991.9.3.464. [DOI] [PubMed] [Google Scholar]
  6. Kris M. G., Gralla R. J., Burke M. T., Berkowitz L. D., Marks L. D., Kelsen D. P., Heelan R. T. Phase II trial of oral piritrexim (BW301U) in patients with stage III non-small cell lung cancer. Cancer Treat Rep. 1987 Jul-Aug;71(7-8):763–764. [PubMed] [Google Scholar]
  7. Laszlo J., Brenckman W. D., Jr, Morgan E., Clendeninn N. J., Williams T., Currie V., Young C. Initial clinical studies of piritrexim. NCI Monogr. 1987;(5):121–125. [PubMed] [Google Scholar]
  8. Sedwick W. D., Hamrell M., Brown O. E., Laszlo J. Metabolic inhibition by a new antifolate, 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methyl-pyrido[2,3-d]pyrimidine (BW3O1U), an effective inhibitor of human lymphoid and dihydrofolate reductase-overproducing mouse cell lines. Mol Pharmacol. 1982 Nov;22(3):766–770. [PubMed] [Google Scholar]
  9. Sigel C. W., Macklin A. W., Woolley J. L., Jr, Johnson N. W., Collier M. A., Blum M. R., Clendeninn N. J., Everitt B. J., Grebe G., Mackars A. Preclinical biochemical pharmacology and toxicology of piritrexim, a lipophilic inhibitor of dihydrofolate reductase. NCI Monogr. 1987;(5):111–120. [PubMed] [Google Scholar]
  10. Uen W. C., Huang A. T., Mennel R., Jones S. E., Spaulding M. B., Killion K., Havlin K., Keegan P., Clendeninn N. J. A phase II study of piritrexim in patients with advanced squamous head and neck cancer. Cancer. 1992 Feb 15;69(4):1008–1011. doi: 10.1002/1097-0142(19920215)69:4<1008::aid-cncr2820690430>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  11. Weiss G. R., Sarosy G. A., Shenkenberg T. D., Williams T., Clendeninn N. J., Von Hoff D. D., Woolley J. L., Liao S. H., Blum M. R. A phase I clinical and pharmacological study of weekly intravenous infusions of piritrexim (BW301U). Eur J Cancer Clin Oncol. 1989 Dec;25(12):1867–1873. doi: 10.1016/0277-5379(89)90360-x. [DOI] [PubMed] [Google Scholar]
  12. de Wit R., Kaye S. B., Roberts J. T., Stoter G., Scott J., Verweij J. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer. 1993 Feb;67(2):388–390. doi: 10.1038/bjc.1993.71. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES